Literature DB >> 16807403

Increased water intake decreases progression of polycystic kidney disease in the PCK rat.

Shizuko Nagao1, Kazuhiro Nishii, Makoto Katsuyama, Hiroki Kurahashi, Tohru Marunouchi, Hisahide Takahashi, Darren P Wallace.   

Abstract

Renal enlargement in polycystic kidney disease (PKD) is caused by the proliferation of mural epithelial cells and transepithelial fluid secretion into the cavities of innumerable cysts. Arginine vasopressin (AVP) stimulates the proliferation of human PKD cells in vitro via cAMP-dependent activation of the B-Raf/MEK (MAPK/ERK kinase/extracellular signal-regulated kinase (ERK) pathway. ERK activity is elevated in cells that line the cysts in animals with PKD, and AVP receptor antagonists reduce ERK activity and halt disease progression. For suppression of the effect of AVP physiologically, water intake was increased in PCK rats, a model of PKD, and the effect on renal morphology, cellular mechanism, and function was determined. The addition of 5% glucose in the drinking water increased fluid intake approximately 3.5-fold compared with rats that received tap water. In PCK rats, increased water intake for 10 wk reduced urinary AVP excretion (68.3%), and urine osmolality fell below 290 mOsmol/kg. High water intake was associated with reduced renal expression of AVP V2 receptors (41.0%), B-Raf (15.4%), phosphorylated ERK (38.1%), and proliferating cell nuclear antigen-positive renal cells (61.7%). High water intake reduced the kidney/body weight ratio 28.0% and improved renal function. Taken together, these data demonstrate that water intake that is sufficient to cause persistent water diuresis suppresses B-Raf/MEK/ERK activity and decreases cyst and renal volumes in PCK rats. It is suggested that limiting serum AVP levels by increased water intake may be beneficial to some patients with PKD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807403     DOI: 10.1681/ASN.2006030251

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  84 in total

Review 1.  Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Hannah A Blair; Gillian M Keating
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

2.  Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Authors:  Connie J Wang; Catherine Creed; Franz T Winklhofer; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

Review 3.  Potential pharmacological interventions in polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Robert W Schrier
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 5.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

6.  Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Authors:  Vicente E Torres; Eiji Higashihara; Olivier Devuyst; Arlene B Chapman; Ronald T Gansevoort; Jared J Grantham; Ronald D Perrone; John Ouyang; Jaime D Blais; Frank S Czerwiec
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-23       Impact factor: 8.237

7.  Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.

Authors:  Gail A Reif; Tamio Yamaguchi; Emily Nivens; Hiroyuki Fujiki; Cibele S Pinto; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2011-08-03

8.  Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease.

Authors:  Jacob A Torres; Mina Rezaei; Caroline Broderick; Louis Lin; Xiaofang Wang; Bernd Hoppe; Benjamin D Cowley; Vincenzo Savica; Vicente E Torres; Saeed Khan; Ross P Holmes; Michal Mrug; Thomas Weimbs
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

9.  Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.

Authors:  Osama W Amro; Jessica K Paulus; Farzad Noubary; Ronald D Perrone
Journal:  Am J Kidney Dis       Date:  2016-09-20       Impact factor: 8.860

10.  Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease.

Authors:  Romina Mancinelli; Antonio Franchitto; Shannon Glaser; Antonella Vetuschi; Julie Venter; Roberta Sferra; Luigi Pannarale; Francesca Olivero; Guido Carpino; Gianfranco Alpini; Paolo Onori; Eugenio Gaudio
Journal:  Lab Invest       Date:  2016-08-29       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.